Mark Reisenauer is senior vice president, oncology business unit. In this role, he is responsible for commercial activities supporting marketed products, Astellas' co-promotion partners and commercial planning for early stage oncology development compounds. Reisenauer is a member of the Astellas US Management Committee.
Reisenauer joined Astellas in 2011 as vice president, sales and marketing, oncology, where he led commercial activities supporting oncology products, Tarceva and the launch of Xtandi.
Prior to joining Astellas, Reisenauer served as senior vice president and chief commercial officer of Micromet Inc. (now part of Amgen), where he led investor and public relations, new product planning, and commercial launch planning. Previously, Reisenauer held various sales and marketing leadership roles at Abbott, Pharmacia, Bristol-Myers Squibb and AstraZeneca.
Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.